


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 15/28, 7/00, C12P 21/08 G01N 33/53, 33/577, 33/68		A1	(11) International Publication Number: WO 93/24531 (43) International Publication Date: 9 December 1993 (09.12.93)
(21) International Application Number: PCT/GB93/01173 (22) International Filing Date: 2 June 1993 (02.06.93) (30) Priority data: 9211686.2 3 June 1992 (03.06.92) GB (71) Applicant (for GB only): DZIEGLEWSKA, Hanna, Eva [GB/GB]; 95 Lowry Crescent, Mitcham, Surrey CR4 3NZ (GB). (71) Applicant (for all designated States except US): MEDINNOVA SF [NO/NO]; Rikshospitalet, N-0027 Oslo (NO). (72) Inventor; and (75) Inventor/Applicant (for US only): HALL, Christian [NO/NO]; Fürstlia 258, N-1335 Snarøya (NO).			(74) Agents: DZIEGLEWSKA, Hanna, Eva et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.

(54) Title: BNP ANTIBODY AND IMMUNOASSAY USING IT



(57) Abstract

The present invention provides antibodies for use in a method of immunoassay being antibodies specific to the polypeptide comprising amino acids 1-76 of N-terminal brain natriuretic factor BNP(1-76). Also provided are methods and kits for the diagnosis or prognosis of conditions in which BNP(1-76) is a diagnostic or predictive indicator e.g. heart failure or hypervolaemia.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

BNP ANTIBODY AND IMMUNOASSAY USING IT

This invention relates to the N-terminal section of Brain Natriuretic Peptide Prohormone, BNP(1-76) and the use of antibodies against this in immunoassays in biological fluids for the purpose of biological research and medical diagnosis, for example of heart failure or hypervolaemia.

Heart failure is a common clinical syndrome especially among elderly people. Population surveys indicate that the condition affects about 2% of the total population in the western world. The syndrome usually presents itself with an insidious onset with unspecific symptoms such as dyspnea on exertion, fatigue and peripheral oedemas. To establish the diagnosis the physician usually must either rely on his clinical experience or refer the patient to a cardiological center for echocardiography, radionuclide scanning, exercise testing or catheterization.

Heart disease represents a significant drain on health resources in many major countries, and whilst an early diagnosis may help in controlling the condition and preventing rapid progression to severe heart failure, it would obviously be preferable to be able to identify those patients in which heart failure is likely to occur before it actually does so, ie. to prognose rather than diagnose.

Unfortunately, there are at present no completely satisfactory methods for predicting the likelihood of heart failure. Problems frequently observed with such methods are insufficient accuracy and sensitivity, and the disadvantages of the necessity for expensive equipment requiring specially trained personnel (eg. in echocardiography). A need therefore exists for a simple method of accurately and sensitively, not only diagnosing, but also predicting the likelihood of onset

- 2 -

of heart failure.

Whilst heart failure can be defined as a symptomatic state ie. an overt disease or syndrome, patients may frequently pass through a state of asymptomatic cardiac dysfunction ie. a sub-clinical condition without overt symptoms, before heart failure manifests itself. However, we have now found that not all patients having cardiac dysfunction go on to develop severe heart failure, and that the risk of heart failure for some such people is much greater than for others. To be able to identify those people at particular risk of developing heart failure in order that they may be caught and treated before heart failure occurs would be of great clinical importance; at the moment existing treatments eg. ACE inhibitors are very expensive and it is not cost-effective for everyone to be treated to try to prevent the onset of heart failure.

Brain Natriuretic Peptide (BNP) is a polypeptide originally isolated from porcine brain by T. Sudoh and coworkers (Nature 1988; 332: 78-81). After cloning and sequence analysis of cDNA coding for the peptide (T. Sudoh BBRC 1989; 159: 1427-34) human BNP was shown to be produced in the human heart. Human Brain Natriuretic Peptide is believed to be produced in cardiac myocytes as a prohormone (proBNP or BNP(1-108)). proBNP consists of 108 amino acids and is split, before or during secretion, at amino acids Arg76 -- Ser77 into BNP and the N-terminal part of the prohormone, BNP(1-76), that is the peptide consisting of the first 76 amino acids from the N-terminal of proBNP.

The BNP(77-108) plasma concentration is increased in patients suffering from heart disease leading to heart failure. The cardiac monocytes secrete another factor, namely atrial natriuretic factor (ANF) but the secretory response to heart failure or incipient heart failure seems to be much larger in the BNP system compared to the ANF system (Mukoyama et al, J Clin

- 3 -

Invest 1991; 87: 1402-12).

The present invention is based on the concept that BNP(1-76), due to a long half-life as compared with BNP hormone itself and high initial concentration, is a particularly good diagnostic indicator or predictor of heart disease and also of hypervolaemia.

BNP(1-76) may thus be used to provide the basis of either a diagnostic or a prognostic test for heart failure, primarily in the biosynthesis of antibodies for use in such a test but also as competing antigen in competitive binding immunoassays. For such use in making antibodies BNP(1-76) or a fragment thereof may advantageously be conjugated to an immunogenic protein or peptide such as PPD, a protein derivative of tuberculin, Keyhole Limpet Haemocyanin or bovine serum albumin.

Thus BNP(1-76) or an antigenic fragment thereof or polypeptide extension thereof having at least one antigenic epitope of BNP(1-76), conjugated to one or more immunogenic polypeptides, constitutes one aspect of the present invention; these polypeptides may be used to make either polyclonal or monoclonal antibodies specific to BNP(1-76). Such monoclonal and polyclonal antibodies constitute two further aspects of the invention.

According to a still further aspect of the invention we provide a method of immunoassay for BNP(1-76) or a fragment thereof or polypeptide extension thereof wherein the primary binding partner therefor is a monoclonal or polyclonal antibody according to the invention. Methods of immunoassay are of course well known in the art eg. RIA, ELISA, fluorescence immunoassay (FIA) or dry chemistry test strip immunoassays. Such an immunoassay will, in general, use a monoclonal or polyclonal antibody according to the invention in immobilised form, eg. on microtitre plates, membranes or beads, to isolate the target BNP(1-76) compound. In a sandwich assay, the bound antigen may be

- 4 -

labelled using additional soluble antibody according to the invention, which may be monoclonal or polyclonal and which may either carry a label or, more conveniently, may itself be labelled subsequently by reaction with a secondary antibody carrying a label.

Thus, if the primary antibody according to the invention is raised in mice or rabbits, the labelled secondary antibody may be an anti-mouse or anti-rabbit antibody.

Suitable labels include radionucleides, fluorescent substances eg. europium based fluorogens, enzymes, for example as used in ELISA systems employing automated hybrid methods or dyes or coloured particles such as colloidal gold.

Alternatively, a competitive binding assay may be used, wherein a known quantity of labelled BNP(1-76), or fragment or extension thereof, is added to the analyte solution and contacted with a limited quantity of the immobilised monoclonal or polyclonal antibody, whereby the amount of labelled antigen which is immobilised is inversely proportional to the amount of target antigen present in the analyte.

The invention thus extends to labelled forms of BNP(1-76) or fragments or polypeptide extensions thereof and to labelled forms of the antibodies of the invention.

The invention also comprises a kit for immunoassay of BNP(1-76) or a fragment or polypeptide extension thereof comprising at least:

- (a) a monoclonal or polyclonal antibody according to the invention in immobilised form and, optionally;
- (b) a labelled sample of BNP(1-76) or a fragment or polypeptide extension thereof;
- (c) said monoclonal or polyclonal antibody in non-immobilised form;
- (d) a labelled secondary antibody specific to said antibody (c).

- 5 -

Such an immunoassay and kit may be used in research into related biological systems as well as for diagnosis or prognosis of conditions wherein the BNP(1-76) level in body fluids is a diagnostic or predictive indicator.

The invention also comprises a method of diagnosis or prognosis of a condition in which the concentration of BNP(1-76) or a fragment or polypeptide extension thereof is a diagnostic or predictive indicator, wherein a body fluid of a patient is subjected in vitro to immunoassay to detect or assay the presence or quantity therein of BNP(1-76).

We have recently found that another natriuretic factor namely pro-ANF, and in particular N-terminal pro-ANF, can serve as an indicator of risk of heart failure in patients lacking overt symptoms of heart failure. The level of pro-ANF in body fluids can be directly related to the risk of heart failure, predominantly related to increased atrial pressure. In contrast, BNP(1-76) is predominantly an indication of a heart condition related to increased ventricular pressure. BNP(1-76) as a fragment or polypeptide extension thereof can also be used to assess risk of heart failure in addition to its use in diagnosis of actual heart failure. Furthermore, assay of both N-terminal pro-ANF and BNP(1-76) in body fluids can assist in determining whether atrial or ventricular pressure is concerned.

Thus, the immunoassay can be used in the monitoring of heart failure treatment. Such treatment is aimed at reducing the hypervolemia and excessive vasoconstriction seen in heart failure by the administration of diuretics and vasodilators. By decreasing the pressure in the cardiac chambers such treatment will lower cardiac production of BNP(1-76). The resultant decrease in plasma BNP(1-76) concentration serve to inform the physician of a significant drug effect. On the contrary, an increase in plasma BNP(1-76) indicates that an adjustment of dosage might be necessary.

- 6 -

Although less well documented at this time BNP(1-76) may also be used as a diagnostic tool in the diagnosis of hypervolemia without heart failure. The immunoassay therefore has potential use also in the in-hospital intensive care setting where monitoring of volume status is essential.

The body fluid on which the immunoassay is performed may be any body fluid in which the BNP(1-76) is located, but conveniently will be plasma or serum. In some cases it may be convenient to extract the peptide, or otherwise treat the sample prior to assay.

The BNP(1-76) peptide or an antigenic or immunogenic fragment thereof may be produced by synthesis from its constituent amino acids or by assembly of pre-synthesised blocks of amino acids using techniques well known in the art. Where labelled material is required, the label may be introduced by standard techniques.

For the purpose of raising monoclonal or polyclonal antibodies, the BNP(1-76) or fragment thereof may be conjugated to an immunogenic protein or peptide, for example PPD, a protein derivative of tuberculin, eg. using 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide according to the method of Staros et al (Analyte Biochem 1986; 156: 220-222).

The antibodies of the invention may be made by injecting a host animal, eg. a mouse or rabbit, with the BNP antigen of the invention, advantageously a conjugate with an immunogenic protein as described above, to provide either a serum containing polyclonal antibodies or spleen cells for conversion to hybridomas or immortalised cell lines producing monoclonal antibodies.

The following Examples are given by way of illustration only with reference to the accompanying drawing in which:

Figure 1 shows a standard curve for immunoassay for BNP(1-76) using synthetic BNP(47-64) as immunogen,

- 7 -

standard and tracer, and polyclonal rabbit antibody. (Abscissa shows BNP(47-64) pmol/l; ordinate shows % binding (B/B(O))).

Example 1

Production of monoclonal antibody against BNP(1-76)

1) Conjugation

Three synthesized fragments of BNP(1-76): BNP(1-21), BNP(22-46) and BNP(47-64) were acquired from Peninsula laboratories and conjugated to PPD (protein derivative of tuberculin) according to Staros et al (Analyt Biochem 1986; 156: 220-222).

2) Immunization

Balb C mice, preimmunized with BCG antigen were utilized. The mice received a 50 microgram mixture of the three conjugates in 200 μ l of Freund's incomplete adjuvant. The mixture was given in 2 x 200 μ l injections on 2 occasions 2 weeks apart. 2 weeks after the last injection 50 μ g of conjugate mixture in saline was injected intraperitoneally.

3) Fusion

3 days after intraperitoneal immunization mouse splenic cells were fused with SP 2/0 myeloma cells and the resultant hybridomas selected in HAT medium. The suspension of hybridomas was distributed in 960 wells in Dulbeccos medium enriched with 10% human endothelial cell supernatant.

4) Screening

Method 1

Costar microtiter plates were coated with a mixture of the synthetic BNP peptide sequences (0.5 μ g/ml).

- 8 -

Supernatants were then added and binding of antibody from supernatants was screened by ELISA through the addition of anti mouse IgG conjugated to horseradish peroxidase enzyme followed by substrate solution (OPD).

Method 2

An alternative method of screening is to coat Greiner microtiter plates with goat anti mouse IgG (1.0 µg/ml). Supernatants are then added and incubated. Biotinylated synthetic BNP peptide sequences are added and the ability of supernatants to bind peptide are screened by ELISA through the addition of streptavidin-conjugated horseradish peroxidase enzyme followed by substrate solution (OPD).

5) Cloning

Hybridomas producing antibodies to the peptide mixture were cloned and subcloned in two runs. Clone 1C7 was shown to react with peptide sequence BNP(47-64). This clone was grown and the supernatant utilised in immunoassay for BNP(1-76).

Example 2

Immunoassay for BNP(1-76)

The 1C7 antibody can be utilised in various types of immunoassays for BNP(1-76). These include

- a) Radioimmunoassay (RIA)
- b) Europium Fluorescence immunoassays (FIA)
- c) Enzyme linked immunosorbent assays (ELISA) including automated hybrid methods running on micro titer plates or membranes
- d) Various dry-chemistry test strip immunoassays

The following is an example of a sandwich ELISA.

- 9 -

Costar microtiter plates are precoated with the 1C7 antibody. Sample or standard is added to the wells and after 2 hours of incubation the wells are washed and a secondary antibody (polyclonal or monoclonal) towards BNP(1-76) is added. Again after 2 hours a horseradish peroxidase-labelled anti mouse (rabbit) antibody is supplied and finally after the addition of O-phenylene-diamine substrate the colour is read in a platereader.

Example 3

Immunoassay for BNP(1-76) utilizing polyclonal rabbit antibody

A synthetic peptide subsequence of BNP(1-76), in this case BNP(47-64), was conjugated to PPD according to Staros et al. (Supra). Rabbits were BCG vaccinated and then repeatedly immunized with the conjugated peptide.

Iodination (^{125}I) of synthetic BNP(47-64), with a tyrosine group added at the N-terminal end, was done by the chloramine-T method as follows:

Chloramine-T Method

- 1) 5 μg of the synthetic peptide was reconstituted with 20 μl sodiumphosphate buffer (0.25 M, pH 7.5).
- 2) Approximately 5 μl of ^{125}I was added (0.5 mCi).
- 3) 5 μl of chloramine-T (1 mg/ml) was added and incubated for 45 seconds.
- 4) 5 μl of sodiummetabisulphite (1 mg/ml) was added and incubated for 45 seconds.
- 5) The mixture was then fractionated on a column with Sephadex G10.

- 10 -

- 6) The fractions were counted with a gamma-counter, and the fraction/fractions with highest counts per minute (cpm) were selected as tracer for use in the RIA methods.

Sample or standards (BNP[47-64]), together with tracer (iodinated BNP(47-64)) and polyclonal antibody from rabbit serum, are mixed in polystyrene assay tubes. After 48 hours of incubation at 4°C, normal serum from rabbit, and goat anti-rabbit IgG are added. After 2 hours of incubation, polyethyleneglycol (PEG) is added and the samples are centrifuged. The supernatant is removed and the counts per minute (cpm) in precipitate are measured with a gammacounter. An example of a standard curve obtained by this type of assay is shown in Figure 1.

- 11 -

Claims

1. Antibodies for use in a method of immunoassay being antibodies specific to the polypeptide comprising amino acids 1-76 of N-terminal brain natriuretic factor BNP(1-76).
2. Antibodies as claimed in claim 1 being monoclonal antibodies.
3. Antibodies as claimed in claim 1 being polyclonal antibodies.
4. Antibodies as claimed in any of claims 1 to 3 carrying a label.
5. Antibodies as claimed in claim 1 in which the label is a radionuclide, a fluorescent substance, an enzyme, a dye or coloured particles.
6. Antibodies as claimed in any of claims 1 to 5 in immobilised form.
7. A method of immunoassay for BNP(1-76) or a fragment thereof or polypeptide extension thereof wherein the primary binding partner therefor is a monoclonal or polyclonal antibody according to any one of claims 1 to 6.
8. A method as claimed in claim 7 in which the antibody is immobilised as microtitre plates, membranes or beads.
9. A method as claimed in claim 8 in which a secondary antibody against BNP(1-76) is used in a sandwich assay and is labelled before or after reaction with BNP(1-76).

- 12 -

10. A method as claimed in claim 9 in which a known quantity of labelled BNP(1-76) or a fragment or polypeptide extension thereof is added to an analyte solution and contacted with a limited quantity of immobilised antibody against BNP(1-76) to provide a competitive binding assay.
11. Labelled BNP(1-76) or a fragment or polypeptide extension thereof.
12. BNP(1-76) or an antigenic fragment thereof or polypeptide extension thereof having at least one antigenic epitope of BNP(1-76), conjugated to one or more immunogenic polypeptides.
13. A kit for immunoassay of BNP(1-76) or a fragment or polypeptide extension thereof comprising at least:
 - (a) a monoclonal or polyclonal antibody according to the invention in immobilised form and, optionally;
 - (b) a labelled sample of BNP(1-76) or a fragment or polypeptide extension thereof;
 - (c) said monoclonal or polyclonal antibody in non-immobilised form;
 - (d) a labelled secondary antibody specific to said antibody (c).
14. A method of diagnosis or prognosis of a condition in which the concentration of BNP(1-76) or a fragment or polypeptide extension thereof is a diagnostic or predictive indicator, wherein a body fluid of a patient is subjected in vitro to immunoassay to detect or assay the presence or quantity therein of BNP(1-76).
15. A method for the production of an antibody as claimed in claim 1 wherein BNP(1-76) or a fragment or polypeptide extension thereof, if necessary conjugated to an immunogenic protein or polypeptide, is injected

- 13 -

into a host animal to provide a serum containing a polyclonal antibody or spleen cells which are subsequently converted to hybridomas or immortalised cell lines producing monoclonal antibodies.

1/1




Figure 1

INTERNATIONAL SEARCH REPORT

PCT/GB 93/01173

International Application No.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)*		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07K15/28; G01N33/577;	C07K7/00; G01N33/68	C12P21/08; G01N33/53
II. FIELDS SEARCHED		
Minimum Documentation Searched?		
Classification System	Classification Symbols	
Int.Cl. 5	C07K ; C12P ; G01N	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁴		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁷		
Category ⁸	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claims No. ¹³
X	JAPANESE PATENTS ABSTRACTS (UNEXAMINED) Section Ch, Week 9207, Derwent Publications Ltd., London, GB; Class CH, AN 92-053618 & JP,A,3 297 392 (SHIONOGI KK) 27 December 1991 see abstract.	1-10
X	CHEMICAL ABSTRACTS, vol. 114, no. 25, 24 June 1991, Columbus, Ohio, US; abstract no. 240736k, TOGASHI, KAZUYOSHI ET AL. 'A specific and highly sensitive radioimmunoassay of human brain natriuretic peptide' page 108 ;column L ; & RHINSHO BYORI vol. 39, no. 3, 1991, JAPAN; pages 283 - 288 see abstract	1-10
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
25 AUGUST 1993		14 -09- 1993
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		HORNIG H.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	J. CLIN. INVEST. vol. 87, no. 4, April 1991, AM. SOC. CLIN. INVEST., pages 1402 - 1412 M. MUKOYAMA ET AL. 'Brain natriuretic peptide as a novel cardiac hormone in humans' cited in the application see page 1404, left column, paragraph 6 - page 1408, right column, paragraph 2 ---	1-15
A	EP,A,0 385 476 (DAIICHI PURE CHEMICALS CO.) 5 September 1990 see page 2, line 45 - page 3, line 3; claims 1-9 -----	1-15

GB 9301173
SA 74642

25/08/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0385476	05-09-90	JP-A- 2231082 JP-A- 2237999	13-09-90 20-09-90

SEP 20 8M 2007

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.